Table 1 Baseline comparison of children randomized to daily and three times a week dosing schedule.
Baseline characteristics | Daily (n= 128) | Three times a week (n= 148) | Total (n= 276) | P*Value |
|---|---|---|---|---|
Sex (%) | Â | Â | Â | Â |
   Male | 57.0 | 55.4 | 56.3 | 0.81 |
Age (months) | Â | Â | Â | 0.45 |
   Median | 29.7 | 21.8 | 25.9 |  |
   (IQR) | (13.1 to 47.7) | (10.2 to 52.6) | (11.9 to 51.0) |  |
Age (years; %) | Â | Â | Â | 0.50 |
   < 1 year | 23.4 | 26.4 | 25.0 |  |
   1-4 years | 51.6 | 44.6 | 47.8 |  |
   > 4 years | 25.0 | 29.0 | 27.1 |  |
Study drug (%) | Â | Â | Â | 0.39 |
   Placebo | 35.2 | 40.5 | 38.0 |  |
   Isoniazid | 64.8 | 59.5 | 62.1 |  |
Site (%) | Â | Â | Â | 0.55 |
   RCCH | 52.3 | 48.0 | 50.0 |  |
   TCH | 47.7 | 52.0 | 50.0 |  |
CDC clinical stage (%) | Â | Â | Â | 0.95 |
   N or A | 14.8 | 13.5 | 14.1 |  |
   B | 65.6 | 66.9 | 66.3 |  |
   C | 19.5 | 19.6 | 19.6 |  |
CDC immune stage (%) | Â | Â | Â | 0.09 |
   1 | 22.7 | 34.5 | 29.0 |  |
   2 | 46.1 | 37.2 | 41.3 |  |
   3 | 31.2 | 28.4 | 29.7 |  |
On HAART at randomization (%) | 10.9 | 9.5 | 10.1 | 0.7 |
Started HAART during study (%) | 64.8 | 58.8 | 61.6 | 0.32 |
No tap water in house (%) | 50.0 | 53.7 | 52.2 | 0.63 |
No electricity in house (%) | 16.5 | 23.7 | 20.3 | 0.18 |
No flush toilet in house (%) | 55.1 | 56.8 | 56.0 | 0.81 |
Not a brick house (%) | 41.7 | 45.6 | 43.8 | 0.54 |
Number of people living in house | Â | Â | Â | 0.5 |
   Med | 5 | 5 | 5 |  |
   (IQR) | (3 to 6) | (4 to 6.5) | (3 to 6) |  |
Number of people in house (%) | Â | Â | Â | 0.31 |
   ≤ 5 | 67.7 | 61.5 | 64.4 |  |
   > 5 | 32.3 | 38.5 | 35.6 |  |